Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells $908,600.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 27,500 shares of the company's stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Collegium Pharmaceutical Stock Down 1.8 %

NASDAQ:COLL opened at $33.18 on Wednesday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a 50 day moving average of $30.57 and a 200-day moving average of $34.10. The firm has a market capitalization of $1.07 billion, a PE ratio of 14.30 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 52 week low of $28.39 and a 52 week high of $42.29.

Analyst Ratings Changes

Several brokerages recently weighed in on COLL. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Piper Sandler reiterated a "neutral" rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.80.




Check Out Our Latest Stock Report on COLL

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in COLL. TD Private Client Wealth LLC boosted its holdings in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after acquiring an additional 483 shares during the period. Foundry Partners LLC boosted its stake in Collegium Pharmaceutical by 3.3% during the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company's stock valued at $610,000 after purchasing an additional 509 shares during the period. CWM LLC grew its position in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after purchasing an additional 736 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 792 shares during the period. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Collegium Pharmaceutical by 4.4% in the third quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company's stock valued at $908,000 after purchasing an additional 983 shares during the period.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Collegium Pharmaceutical?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Collegium Pharmaceutical and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles